11,125 Shares in Abbott Laboratories $ABT Bought by CenterBook Partners LP

Posted by George Bondi on Jun 11th, 2026

CenterBook Partners LP acquired a new position in shares of Abbott Laboratories (NYSE:ABT – Free Report) during the 4th quarter, Holdings Channel.com reports. The firm acquired 11,125 shares of the healthcare product maker’s stock, valued at approximately $1,394,000.

Several other large investors have also recently added to or reduced their stakes in ABT. Freemont Management S.A. lifted its stake in Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after buying an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab bought a new stake in Abbott Laboratories in the fourth quarter valued at $116,580,000. Thrivent Financial for Lutherans lifted its stake in Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after buying an additional 48,286 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new stake in Abbott Laboratories in the third quarter valued at $185,640,000. Finally, Net Worth Advisory Group bought a new stake in Abbott Laboratories in the fourth quarter valued at $1,366,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott continues to gain attention for its cancer diagnostics growth story, with the Exact Sciences acquisition expanding its diagnostics portfolio and supportive screening data improving the long-term outlook. Mounting Evidence Backs Abbott’s Cancer Diagnostics Growth Story
Positive Sentiment: Abbott also received a boost from news that it secured CE Mark for its Libre Duo dual glucose-ketone sensing technology, a potential growth driver in diabetes care. Abbott (ABT) Secures CE Mark for World’s First Dual Glucose-Ketone Sensing Technology for Diabetes
Neutral Sentiment: ABT is being highlighted as a trending stock across financial media, suggesting rising investor interest but not necessarily a clear catalyst by itself. Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Neutral Sentiment: Analyst commentary also noted Abbott as a blue-chip, defensive name for long-term portfolios, reinforcing its stability and dividend appeal rather than signaling a near-term earnings surprise. New Investors: 3 Rock-Solid Stocks to Build Your Portfolio Around
Negative Sentiment: Despite the positive business updates, the stock has still been trading lower, reflecting broader selling pressure and investor caution after recent gains. Abbott (ABT) Dips More Than Broader Market: What You Should Know

Insider Buying and Selling

In related news, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by insiders.

Abbott Laboratories Stock Down 2.3%

NYSE ABT opened at $89.15 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The company’s 50 day simple moving average is $92.01 and its 200 day simple moving average is $108.39. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $139.06. The company has a market capitalization of $155.29 billion, a P/E ratio of 24.97, a PEG ratio of 1.52 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the previous year, the firm earned $1.09 EPS. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of research analyst reports. Citigroup lowered their price target on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, April 17th. BTIG Research reissued a “buy” rating and set a $131.00 price target on shares of Abbott Laboratories in a report on Monday, April 27th. Oppenheimer lowered their price target on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Evercore lowered their price target on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Finally, Leerink Partners lowered their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.09.

Read Our Latest Research Report on ABT

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.